Directorate Change

ADMIN

Fri, Sep 02 2022 08:30 am

Legal Entity Identifier: 5493007C3I0O5PJKR078

1 September 2022

JPMorgan Global Growth & Income plc

Combination with The Scottish Investment Trust PLC

Appointment of New Directors

Further to the announcement on 5 August 2022, pursuant to the combination of The Scottish Investment Trust PLC ("SCIN") and JPMorgan Global Growth & Income plc (the "Company"), the Board is pleased to announce the appointment of James Will, Jane Lewis, Mick Brewis and Neil Rogan as non-executive directors of the Company with effect from today.

The Board will initially consist of eight directors, comprising four directors from the current Board and four directors from the board of SCIN. It is intended currently that James Will and Gay Collins will subsequently retire from the Board at the Company's Annual General Meeting expected to be held in November 2022.

James Will is chair of Asia Dragon Trust plc and a director of Herald Investment Trust plc.

Jane Lewis is chair of Invesco Perpetual UK Smaller Companies Investment Trust PLC and a director of BlackRock World Mining Trust plc, CT UK Capital and Income Investment Trust PLC and Majedie Investments PLC.

Mick Brewis has a non-executive advisory role with Castlebay Investment Partners and is a trustee
of the National Library of Scotland Foundation.

Neil Rogan is chair of both Murray Income Trust PLC and Invesco Asia Trust plc.

There is no other information to be disclosed under FCA Listing Rule 9.6.13 (1) to (6) in relation to James Will, Jane Lewis, Mick Brewis or Neil Rogan.

Capitalised terms used but not defined in this announcement will have the same meaning as set out in the circular published by the Company on 5 August 2022.

Please refer the associated PDF to view the full announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.